SMT202100022T1 - Arimoclomol per il trattamento di disturbi associati a glucocerebrosidasi - Google Patents

Arimoclomol per il trattamento di disturbi associati a glucocerebrosidasi

Info

Publication number
SMT202100022T1
SMT202100022T1 SM20210022T SMT202100022T SMT202100022T1 SM T202100022 T1 SMT202100022 T1 SM T202100022T1 SM 20210022 T SM20210022 T SM 20210022T SM T202100022 T SMT202100022 T SM T202100022T SM T202100022 T1 SMT202100022 T1 SM T202100022T1
Authority
SM
San Marino
Prior art keywords
arimoclomol
associated disorders
treating
glucocerebrosidase associated
treating glucocerebrosidase
Prior art date
Application number
SM20210022T
Other languages
English (en)
Inventor
Anders Mørkeberg Hinsby
Thomas Kirkegaard Jensen
Cathrine Kolster Fog-Tønnesen
Nikolaj Havnsøe Torp Petersen
Claus Bornaes
Original Assignee
Orphazyme As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orphazyme As filed Critical Orphazyme As
Publication of SMT202100022T1 publication Critical patent/SMT202100022T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SM20210022T 2016-04-29 2017-04-28 Arimoclomol per il trattamento di disturbi associati a glucocerebrosidasi SMT202100022T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201670281 2016-04-29
EP17720480.7A EP3448382B1 (en) 2016-04-29 2017-04-28 Arimoclomol for treating glucocerebrosidase associated disorders
PCT/EP2017/060205 WO2017186919A1 (en) 2016-04-29 2017-04-28 Arimoclomol for treating glucocerebrosidase associated disorders

Publications (1)

Publication Number Publication Date
SMT202100022T1 true SMT202100022T1 (it) 2021-03-15

Family

ID=58645076

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20210022T SMT202100022T1 (it) 2016-04-29 2017-04-28 Arimoclomol per il trattamento di disturbi associati a glucocerebrosidasi

Country Status (22)

Country Link
US (3) US20190111041A1 (it)
EP (2) EP3782624B1 (it)
JP (2) JP6818045B2 (it)
KR (2) KR102254140B1 (it)
CN (1) CN109069496A (it)
AU (2) AU2017255959B2 (it)
BR (1) BR112018070653A2 (it)
CA (1) CA3021900A1 (it)
CY (1) CY1123717T1 (it)
DK (1) DK3448382T3 (it)
ES (1) ES2831764T3 (it)
HR (1) HRP20210047T1 (it)
HU (1) HUE052158T2 (it)
IL (2) IL262411B (it)
LT (1) LT3448382T (it)
PL (1) PL3448382T3 (it)
PT (1) PT3448382T (it)
RS (1) RS61291B1 (it)
RU (2) RU2021117465A (it)
SI (1) SI3448382T1 (it)
SM (1) SMT202100022T1 (it)
WO (1) WO2017186919A1 (it)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9662375B2 (en) * 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
WO2021260120A1 (en) * 2020-06-24 2021-12-30 Orphazyme A/S Arimoclomol for treating gaucher disease
KR20230128462A (ko) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03503410A (ja) 1988-03-18 1991-08-01 ザ・ジェネラル・ホスピタル・コーポレーション ヒト熱ショック因子
WO1994029459A1 (en) 1993-06-04 1994-12-22 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
DE69532605T2 (de) 1994-03-21 2005-02-17 Rijksuniversiteit Utrecht Peptidfragmente von mikrobiellen stressproteinen und daraus hergestellte pharmazeutische zusammensetzungen für die behandlung und vorbeugung von entzündungserkrankungen
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
HU222994B1 (hu) 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
US5962313A (en) 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
CA2265935C (en) 1996-09-20 2006-09-05 The University Of New Mexico Heat shock protein complexes
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
WO1999037319A1 (en) 1998-01-23 1999-07-29 National Jewish Medical And Research Center Method for treating inflammatory diseases using heat shock proteins
ATE359084T1 (de) 1998-02-20 2007-05-15 Univ Miami Modifizierter hitzeschockprotein/peptidantigen komplex
ATE297750T1 (de) 1998-03-27 2005-07-15 Gabriele Prof Dr Multhoff Verwendung von hsp70 protein
FR2777890B1 (fr) 1998-04-22 2000-12-29 Roussy Inst Gustave Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
HU226617B1 (en) 1998-12-14 2009-04-28 Cytrx Corp Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient
HUP9900475D0 (en) * 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
WO2001017554A1 (en) 1999-09-10 2001-03-15 Fordham University Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins
US20020039583A1 (en) 1999-09-30 2002-04-04 Subjeck John R. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US20030236300A1 (en) 1999-10-27 2003-12-25 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
AU1582801A (en) 1999-11-05 2001-06-06 Board Of Regents Of The University Of Nebraska, The Methods and compositions for protection against bovine herpesvirus
US6964851B2 (en) 1999-12-07 2005-11-15 Stressgen Biotechnologies Corp. Compositions and methods for detecting stress-inducible proteins
GB9930443D0 (en) 1999-12-22 2000-02-16 King S College London Novel use of heat shock proteins
US20020127219A1 (en) 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
US20010034042A1 (en) 2000-01-20 2001-10-25 Srivastava Pramod K. Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
AU2001227960A1 (en) 2000-01-21 2001-07-31 University Of Connecticut Health Center Heat shock/stress protein complexes as vaccines against neurodegenerative disorders
WO2001052877A1 (en) 2000-01-21 2001-07-26 University Of Connecticut Health Center Compositions and methods to treat neurodegenerative disorders
HUP0001583A2 (hu) 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20020037290A1 (en) 2000-08-07 2002-03-28 Armen Garo H. Compositions comprising heat shock proteins or alpha(2) macroglobulin, antigenic molecules and saponins, and methods of use thereof
US7517948B2 (en) 2000-09-13 2009-04-14 Multimmune Gmbh Hsp70 peptide stimulating natural killer (NK) cell activity and uses thereof
CA2422867A1 (en) 2000-09-15 2002-04-25 University Of Connecticut Health Center Improved formulations using heat shock/stress protein-peptide complexes
US20020172682A1 (en) 2000-10-20 2002-11-21 University Of Connecticut Health Center Using heat shock proteins to increase immune response
IT1319277B1 (it) 2000-10-24 2003-09-26 Chiesi Farma Spa Proteine di fusione utili per il trattamento di immunizzazione dellamalattia di alzheimer.
AU2002239462A1 (en) 2000-11-03 2002-06-03 The Board Of Regents Of The University Of Nebraska Compositions for protection against bovine viral diseases
EP1209226A3 (en) 2000-11-07 2002-06-05 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70)
US20020142299A1 (en) 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
JP2004522763A (ja) 2001-02-20 2004-07-29 ユーエイビー リサーチ ファンデーション リソソーム蓄積症のアミノグリコシド治療
CA2457008A1 (en) 2001-08-20 2003-02-27 University Of Connecticut Health Center Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin useful for the treatment of cancer and infectious disease
US20050267020A1 (en) 2001-09-27 2005-12-01 Olivier Faure Polypeptides derived from inducible hsp70 and pharmaceutical compositions containing the same
HU0103939D0 (en) 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
GB0123756D0 (en) 2001-10-03 2001-11-21 King S College London A novel chaperone-type of adjuvant for vaccination - Basic 1
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
ITMI20012573A1 (it) 2001-12-06 2003-06-06 D B P Dev Biotechonologica L P Gli acilsalicilati:una nuova classe di induttori di risposta heat shock
CN1615296A (zh) 2002-01-11 2005-05-11 拜奥列克斯研究发展公司 甲脒衍生物及其在治疗血管疾病中的用途
AU2003218639A1 (en) 2002-01-24 2003-09-02 Universiteit Gent Tumour treatment compositions comprising hsp70 and tumour necrosis factor
JP4632664B2 (ja) 2002-02-13 2011-02-16 デューク ユニバーシティ 非ペプチド結合ストレス応答性ポリペプチドによる免疫応答の調節
IL148401A0 (en) 2002-02-26 2002-09-12 Hadasit Med Res Service Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases
WO2003086452A2 (en) 2002-04-05 2003-10-23 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy
US6984389B2 (en) 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
RU2376029C2 (ru) 2002-04-25 2009-12-20 Юниверсити Оф Коннектикут Хелт Сентер Применение белков теплового шока для улучшения терапевтического эффекта невакцинного лечебного воздействия
KR20050007375A (ko) 2002-05-02 2005-01-17 유니버시티 오브 코네티컷 헬스 센터 항체 치료의 효능을 개선하기 위한 열 충격 단백질의 사용
AU2003301296A1 (en) 2002-05-02 2004-05-04 University Of Connecticut Health Center Using heat shock proteins and alpha-2-macroglobulins to increase immune response to vaccines
GB0216414D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
WO2004024097A2 (en) 2002-09-16 2004-03-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
DK1625148T3 (da) 2003-05-21 2013-01-14 Biotech Tools Sa Peptidkompleks
US7244616B2 (en) 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
HUP0303584A3 (en) 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
DE60335549D1 (de) 2003-11-12 2011-02-10 Alfa Biogene Internat B V Gewinnung von Hitzeschockproteinen
EP1691819A4 (en) 2003-11-25 2009-05-06 Sinai School Medicine THERAPY ON CHAPERON BASIS FOR NIEMANN PICK DISEASE
ES2484340T3 (es) 2003-12-05 2014-08-11 Multimmune Gmbh Anticuerpos anti hsp70 terapéuticos y diagnósticos
US20060009520A1 (en) 2004-05-12 2006-01-12 Tall Alan R Retinoid-based methods for altering macrophage cholesterol
WO2005120558A2 (en) 2004-05-25 2005-12-22 University Of Connecticut Health Center Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease
AU2005312415B2 (en) 2004-12-10 2012-02-02 Angteq B.V. Heat shock proteins (HSP) and supraventricular arrhythmia
CN104771402A (zh) 2005-06-08 2015-07-15 阿米库斯治疗学公司 溶酶体酶编码基因突变相关的cns紊乱的治疗
WO2007041285A2 (en) 2005-09-29 2007-04-12 Viral Genetics, Inc. Complexes of inactivated pepsin fraction and heat shock protein
KR20130034062A (ko) 2005-11-08 2013-04-04 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제
US20080039400A1 (en) 2006-01-24 2008-02-14 Universiteit Utrecht Uu Holding B.V. Treatment and prevention of inflammatory bowel diseases
US20100004277A1 (en) 2006-01-26 2010-01-07 Foldrx Pharmaceuticals, Inc. Compounds and methods for modulating protein trafficking
EP2021352A4 (en) 2006-05-19 2009-10-28 Scripps Research Inst TREATMENT OF POOR FOLDING OF PROTEINS
MX2009000032A (es) 2006-06-23 2009-01-23 Amicus Therapeutics Inc Metodo para el tratamiento de trastornos neurologicos por la mejora de la actividad de la beta-glucocerebrosidasa.
WO2008005937A2 (en) 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibiton of hsp90
TW200824678A (en) 2006-08-11 2008-06-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
WO2008047243A2 (en) 2006-08-29 2008-04-24 Forhumantech. Co., Ltd. Pharmaceutical composition for suppression of apoptosis and method for delivering the same
US20080227813A1 (en) * 2006-09-26 2008-09-18 Jack Raymond Barber Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration
AU2007328280A1 (en) 2006-12-01 2008-06-12 Cytrx Corporation Hydroxylamine derivatives for the treatment of stroke
CA2680063A1 (en) 2007-02-23 2008-08-28 University Of Florida Research Foundation, Inc. Compositions and methods for treating glycogen storage diseases
US20100184803A1 (en) 2007-03-09 2010-07-22 Link Medicine Corporation Treatment of Lysosomal Storage Diseases
GB0705626D0 (en) 2007-03-23 2007-05-02 Royal Veterinary College Method for enhancing sperm survival
US20100168016A1 (en) 2007-04-11 2010-07-01 The Jackson Laboratory Diagnosis and treatment of diseases caused by misfolded proteins
EP2139323B1 (en) 2007-04-13 2013-08-21 Amicus Therapeutics, Inc. Treatment of gaucher disease with specific pharmacological chaperones and monitoring treatment using surrogate markers
CA2943032C (en) 2007-04-25 2019-05-07 Cytochroma Inc. Oral controlled release compositions comprising vitamin d compound and waxy carrier
CA2685332A1 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
TW200901958A (en) 2007-05-04 2009-01-16 Cytrx Corp Diabetic wound healing
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
WO2009008719A2 (en) 2007-07-06 2009-01-15 Universiteit Utrecht Holding B.V. Treatment and prevention of inflammatory diseases and autoimmune diseases
WO2009036349A1 (en) 2007-09-12 2009-03-19 Anaphore, Inc. Hsp70-based treatment for autoimmune diseases
WO2009066069A1 (en) 2007-11-21 2009-05-28 Summit Corporation Plc Treatment of protein folding disorders
WO2009073564A1 (en) 2007-11-29 2009-06-11 The Hospital For Sick Children Compositions and methods for treating lysosomal disorders
BRPI0906726A2 (pt) 2008-01-30 2015-07-07 Geron Corp Superfícies sintéticas para a cultura de células em um meio quimicamente definido.
WO2009095452A1 (en) 2008-01-31 2009-08-06 Crystax Pharmaceuticals, S.L. Crystal structure of the atpase domain of proteins of the hsp70 family
JP2011511007A (ja) 2008-02-01 2011-04-07 ザ スクリプス リサーチ インスティチュート タンパク質ホメオスタシスの機能不全を特徴とする状態を治療するための方法
US20110223147A1 (en) 2008-05-07 2011-09-15 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
WO2009137796A2 (en) 2008-05-08 2009-11-12 Northwestern University Method of regulating the heat shock response
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
AU2009262670B2 (en) * 2008-06-26 2013-06-20 Zevra Denmark A/S Use of Hsp70 as a regulator of enzymatic activity
US20110237538A1 (en) 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010022461A1 (en) 2008-08-29 2010-03-04 Children, Youth And Women's Health Service Sulphated sugars to increase activity of sulphatases en lysosomal storage disorders
JP2012504143A (ja) 2008-09-29 2012-02-16 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の用量単位
WO2010053655A2 (en) 2008-11-07 2010-05-14 University Of Kansas Therapeutic methods with withaferin a and analogs
EP2391229B1 (en) 2009-01-29 2015-07-15 Alfa Biogene International B.V. Functional food product comprising heat shock protein or a hydrolysate thereof from alfalfa
EP2218458A1 (en) 2009-02-13 2010-08-18 Fondazione Telethon Molecules able to modulate the expression of at least a gene involved in degradative pathways and uses thereof
EP2405888B1 (en) 2009-03-10 2018-04-11 Alfa Biogene International B.V. Skin care product
GB0906159D0 (en) 2009-04-09 2009-05-20 Summit Corp Plc Drug combination for the treatment of proteostatic diseases
EP3679942A1 (en) 2009-06-17 2020-07-15 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
ES2887552T3 (es) 2009-07-28 2021-12-23 Takeda Pharmaceuticals Co Composiciones y métodos para tratar la enfermedad de Gaucher
WO2011019763A2 (en) 2009-08-10 2011-02-17 The Board Of Trustees Of The University Of Illinois Compositions and methods for the treatment of krabbe and other neurodegenerative diseases
US20110081428A1 (en) 2009-09-16 2011-04-07 The Buck Institute For Age Research Use of thioflavin-like compounds to increase life span and/or health span
US8609416B2 (en) 2009-12-18 2013-12-17 Ventria Bioscience Methods and compositions comprising heat shock proteins
US20120009125A1 (en) * 2010-07-06 2012-01-12 Lombard Jay L Apoe4 and apoj biomarker-based prevention and treatment of dementia
US20130209549A1 (en) 2010-07-21 2013-08-15 University Of South Florida Materials and methods for treating neurodegenerative diseases
US9662375B2 (en) 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
WO2013006076A1 (en) 2011-07-04 2013-01-10 New York University The use of intranasally administered hsp70 protein to treat neurodegenerative diseases
WO2013148333A1 (en) 2012-03-28 2013-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Salicylic acid derivatives useful as glucocerebrosidase activators
US20150284472A1 (en) * 2012-11-05 2015-10-08 Genzyme Corporation Compositions and methods for treating proteinopathies
US9562110B2 (en) 2012-11-21 2017-02-07 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
CA2938577A1 (en) * 2014-02-04 2015-08-13 New York University Progranulin (pgrn) and its derivatives for diagnosis and treatment of lysosomal storage diseases
KR102638203B1 (ko) 2014-09-15 2024-02-19 제브라 덴마크 에이/에스 아리모클로몰 제제
CN107106576A (zh) * 2014-10-10 2017-08-29 弗吉尼亚联邦大学 用于因减弱的瘦蛋白活性和脂质贮积障碍中的至少一种导致的障碍的疗法的氧化胆固醇硫酸酯类

Also Published As

Publication number Publication date
JP2019518725A (ja) 2019-07-04
EP3448382A1 (en) 2019-03-06
KR20190003523A (ko) 2019-01-09
HRP20210047T1 (hr) 2021-04-16
CN109069496A (zh) 2018-12-21
ES2831764T3 (es) 2021-06-09
CY1123717T1 (el) 2022-05-27
WO2017186919A1 (en) 2017-11-02
AU2020277270A1 (en) 2020-12-24
IL280227A (en) 2021-03-01
SI3448382T1 (sl) 2021-03-31
AU2017255959A1 (en) 2018-11-15
US20220133707A1 (en) 2022-05-05
LT3448382T (lt) 2021-04-12
US20200289497A1 (en) 2020-09-17
IL262411A (en) 2018-12-31
JP2021059586A (ja) 2021-04-15
BR112018070653A2 (pt) 2019-02-05
EP3782624A1 (en) 2021-02-24
US11253505B2 (en) 2022-02-22
US20190111041A1 (en) 2019-04-18
RU2750154C2 (ru) 2021-06-22
RU2021117465A (ru) 2021-07-22
CA3021900A1 (en) 2017-11-02
KR20210059796A (ko) 2021-05-25
HUE052158T2 (hu) 2021-04-28
EP3782624B1 (en) 2025-09-10
RS61291B1 (sr) 2021-02-26
PT3448382T (pt) 2020-11-20
AU2017255959B2 (en) 2020-10-15
AU2020277270B2 (en) 2023-02-23
DK3448382T3 (da) 2020-12-07
PL3448382T3 (pl) 2021-02-22
EP3448382B1 (en) 2020-10-14
RU2018138791A (ru) 2020-05-29
JP6818045B2 (ja) 2021-01-20
IL262411B (en) 2021-02-28
KR102254140B1 (ko) 2021-05-24
RU2018138791A3 (it) 2020-06-25

Similar Documents

Publication Publication Date Title
IL291533A (en) Compounds and preparations including them for the treatment of diseases of the central nervous system
IL279308A (en) Methods for the treatment of heptidine-mediated disorders
IL266530A (en) Fibrosis treatment
IL257252A (en) Methods for treating fgf21-related disorders
PL3206493T3 (pl) Kompozycje i sposoby leczenia zaburzeń OUN
PT3224269T (pt) Composições e métodos para tratamento de distúrbios do snc
PT3261640T (pt) Agonistas de 5ht para tratamento de distúrbios de epilepsia
RS61530B1 (sr) Kompozicije i postupci za lečenje poremećaja cns
IL269082A (en) Methods for treating lysosomal disorders
PT3119911T (pt) Compostos para uso no tratamento da doença de alzheimer em pacientes apoe4+/+
ZA201800831B (en) Compositions and methods for treating and preventing neurodegenerative disorders
IL280227A (en) Arimoclomol for the treatment of glucocerebrosidase-related disorders
EP3262065C0 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSTROGLYCANOPATHY DISEASES
IL271211A (en) Migraine treatment
GB201413532D0 (en) Combination therapy for treating hearing disorders
PT3420084T (pt) Nova abordagem para tratamento de disfunções inflamatórias
GB201602011D0 (en) Treating skin disorders
GB201517995D0 (en) Products for treating psychogenic pain disorders